Oral GLP-1 challenger posts best-in-class Phase 2 weight loss data, now in Phase 3; thesis turns on replicating that efficacy at scale

Bull

A positive outcome would show continued or deepening weight loss beyond 56 weeks with no meaningful plateau, alongside a tolerable safety and discontinuation profile consistent with the 2.5 mg titration regimen — validating that aleniglipron's efficacy is durable, not transient. This would reinforce confidence in the Phase 3 ACCOMPLISH design, strengthen the best-in-class oral GLP-1 narrative, and underpin the argument that Phase 3 will replicate and extend the Phase 2b signal at scale.

Bear

The primary failure mode is weight regain or a clear plateau emerging at the 72-week mark, suggesting that the impressive 44- to 56-week losses are not maintained — a pattern that would raise questions about aleniglipron's long-term commercial viability relative to injectable GLP-1 agents. A secondary risk is a deteriorating tolerability profile at extended exposure, particularly elevated GI-related discontinuation rates that erode the competitive differentiation of the 2.5 mg titration regimen.